CM-272 is a potent and selective inhibitor of histone methyltransferases, particularly G9a and GLP. Its primary application lies in the field of cancer research, where it is used to study the role of epigenetic modifications in tumorigenesis. By inhibiting G9a/GLP, CM-272 reactivates silenced tumor suppressor genes, making it a valuable tool for understanding and potentially treating cancers driven by epigenetic dysregulation. Additionally, it is employed in preclinical studies to explore its potential as a therapeutic agent for hematologic malignancies and solid tumors. Its ability to modulate gene expression also makes it useful in research focused on cellular differentiation and reprogramming.